Journal of the American College of Cardiology
© 2014 by the American College of Cardiology Foundation
Published by Elsevier Inc.

Vol. 63, No. 13, 2014
ISSN 0735-1097/$36.00
http://dx.doi.org/10.1016/j.jacc.2013.09.082

PRE-CLINICAL RESEARCH

Transcatheter Implantation of Homologous "Off-the-Shelf" Tissue-Engineered Heart Valves With Self-Repair Capacity

Long-Term Functionality and Rapid In Vivo Remodeling in Sheep

Anita Driessen-Mol, PHD,* Maximilian Y. Emmert, MD, PHD,†‡§ Petra E. Dijkman, PHD,† Laura Frese, PHD,† Bart Sanders, MSC,* Benedikt Weber, PHD,†‡ Nikola Cesarovic, PHD,‡ Michele Sidler, MD,|| Jori Leenders, MSC,* Rolf Jenni, MD, MSEE,§ Jürg Grünenfelder, MD,§ Volkmar Falk, MD,§ Frank P. T. Baaijens, PHD,* Simon P. Hoerstrup, MD, PHD*†‡§||

Eindhoven, the Netherlands; and Zürich, Switzerland

Objectives This study sought to evaluate long-term in vivo functionality, host cell repopulation, and remodeling of "off-the-shelf" tissue engineered transcatheter homologous heart valves.

Background Transcatheter valve implantation has emerged as a valid alternative to conventional surgery, in particular for elderly high-risk patients. However, currently used bioprosthetic transcatheter valves are prone to progressive dysfunctional degeneration, limiting their use in younger patients. To overcome these limitations, the concept of tissue engineered heart valves with self-repair capacity has been introduced as next-generation technology.

Methods In vivo functionality, host cell repopulation, and matrix remodeling of homologous transcatheter tissue-engineered heart valves (TEHVs) was evaluated up to 24 weeks as pulmonary valve replacements (transapical access) in sheep (n = 12). As a control, tissue composition and structure were analyzed in identical not implanted TEHVs (n = 5).

Results Transcatheter implantation was successful in all animals. Valve functionality was excellent displaying sufficient leaflet motion and coaptation with only minor paravalvular leakage in some animals. Mild central regurgitation was detected after 8 weeks, increasing to moderate after 24 weeks, correlating to a compromised leaflet coaptation. Mean and peak transvalvular pressure gradients were 4.4 ± 1.6 mm Hg and 9.7 ± 3.0 mm Hg, respectively. Significant matrix remodeling was observed in the entire valve and corresponded with the rate of host cell repopulation.

Conclusions For the first time, the feasibility and long-term functionality of transcatheter-based homologous off-the-shelf tissue engineered heart valves are demonstrated in a relevant pre-clinical model. Such engineered heart valves may represent an interesting alternative to current prostheses because of their rapid cellular repopulation, tissue remodeling, and therewith self-repair capacity. The concept of homologous off-the-shelf tissue engineered heart valves may therefore substantially simplify previous tissue engineering concepts toward clinical translation.
(J Am Coll Cardiol 2014;63:1320–9) © 2014 by the American College of Cardiology Foundation

Valvular heart disease is an important cause of morbidity and mortality (1). The number of patients requiring heart valve replacements is approximately 280,000 annually worldwide (2) and is estimated to triple in the upcoming decades (3). In recent years, transcatheter valve implantations have emerged as a minimally invasive alternative to conventional surgery, in particular for elderly high-risk patients. However, being bioprosthetic in nature (consisting mainly of fixed, ovine, or porcine tissues) the currently used transcatheter prostheses

See page 1330

From the *Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands; †Swiss Center of Regenerative Medicine, University and University Hospital Zürich, Zürich, Switzerland; ‡Center Surgery, Division of Surgical Research, University Hospital Zürich, Zürich, Switzerland; §Heart Center Zürich, University Hospital Zürich, Zürich, Switzerland; and the ||Center of Applied Biotechnology and Molecular Medicine (CABMM), University of Zürich, Zürich, Switzerland. The research leading to these results has received funding from the European Union's Seventh Framework Programme ([FP7/2007-2013]) under grant agreement n° 242008. All authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Driessen-Mol, Emmert, and Dijkman are joint first authors and contributed equally to this work. Drs. Baaijens and Hoerstrup are joint last authors and contributed equally to this work.

Manuscript received July 2, 2013; revised manuscript received September 12, 2013, accepted September 19, 2013.

are inherently associated with progressive dysfunctional degeneration, preventing their broader use in younger patient populations.

While preliminary attempts with decellularized xenogeneic and allogeneic heart valves have only shown limited host cell repopulation in pre-clinical and clinical trials (4–8), the concept of tissue engineered, living, and autologous heart valves with self-repair and remodeling capacity has been proposed as a promising alternative to overcome such limitations (9–15). In 2010, we reported successfully merging transcatheter-based technologies with heart valve tissue engineering (HVTE) on the basis of stem cell methodology (12). However, this "classical" heart valve tissue engineering concept comprising complex multistep procedures such as cell harvest, cell expansion, seeding on scaffolds, bioreactor in vitro culture, and time-critical implantation coordination of the delicate, living engineered autologous heart valves require high logistical and financial efforts. In this regard, the concept of off-the-shelf (decellularized) homologous tissue-engineered heart valves has recently been introduced as a promising alternative to substantially simplify current HVTE approaches toward routine clinical translation (16–18).

In this study and for the first time, we investigate the long-term in vivo functionality, host repopulation capacity, and matrix remodeling of "off-the-shelf" homologous transcatheter tissue-engineered heart valves (TEHVs) as pulmonary valve replacement in sheep.

Methods

In vitro production of homologous cell-based transcatheter TEHV. Living stented TEHVs were engineered as previously described (16,19) on the basis of rapid degrading synthetic scaffolds and vascular-derived cells and decellularized using a series of enzymatic treatments (16). Please see the expanded Methods section in the Online Appendix for further details. Sterilization was obtained by immersion in 70% EtOH and antibiotic treatment. Decellularized TEHVs were stored in fresh M-199 medium at 4°C.

Abbreviations and Acronyms

HVTE = heart valve tissue engineering

sGAG = sulfated glycosaminoglycan

TEHV = tissue-engineered heart valve

Transapical implantation and in vivo performance of TEHVs. To enable transapical delivery, the stented TEHVs (length = 27 mm, outer diameter = 30 mm) were crimped and loaded onto a custom-made inducing system (outer diameter = 12 mm). To evaluate in vivo functionality and host repopulation capacity, TEHVs (n = 12) were transapically implanted as pulmonary valve replacement in adult sheep (pulmonary annulus 24 to 26 mm, age 2.8 ± 0.1 years, weight range 69 ± 2 kg). The remaining valves (n = 5) served as reference (control) valves. All animals received human care. The ethics committee (Veterinäramt, Gesundheitsdirektion, Kanton Zürich [197/2010], Switzerland) approved the study in compliance with the Guide for the Care and Use of Laboratory Animals, published by the National Institutes of Health (NIH publication No. 85-23) (20). Please see the expanded Methods section in the Online Appendix for further details. The appropriate position and functionality of the implanted valve was visualized by angiography. In vivo functionality (heart rate, mean and maximum transvalvular pressure gradient, and grade of insufficiency) was monitored using transesophageal echocardiography during the procedure, immediately after implantation and after 1, 4, 8, 16, and 24 weeks post-operatively. Insufficiency (central regurgitation) was



Figure 1 Angiography of the Implantation Procedure

Function of the native valve was assessed prior to implantation **(A,B)**. The inducing system was inserted **(C)** and the valve was delivered into the pulmonary artery **(D,E)**. Afterward, the position and functionality of the implanted valve was visualized **(F)**. See accompanying Online Video 1.

graded as none to: 1) trivial; 2) mild; 3) moderate; and 4) severe. Anticoagulation therapy was maintained for 7 days after implantation. The TEHVs were explanted within 1 day (n = 2), and after 8 weeks (n = 2), 16 weeks (n = 4), and 24 weeks (n = 4). Photographs were taken from all explanted valves to macroscopically analyze tissue appearance.

Qualitative tissue analyses: (immuno-) histology and scanning electron microscopy. Control (n = 5) and explanted TEHVs (n = 12) were analyzed by (immuno-) histology and scanning electron microscopy. Please see the expanded Methods section in the Online Appendix for further details.

Quantitative tissue analyses: tissue composition. The total amount of DNA, sulfated glycosaminoglycans (sGAGs), and collagen in the leaflets of control (n = 5) and explanted TEHVs after 8 (n = 2), 16 (n = 4), and 24 weeks (n = 4) as well as of native ovine valve leaflets (n = 3) were analyzed using biochemical assays. For each valve 2 samples per leaflet were analyzed, resulting in 6 measurements per valve. These measurements were averaged to represent an average value for each valve. The values for DNA, sGAGs, and collagen are expressed per milligram dry weight. Please see the expanded Methods section in the Online Appendix for further details on the assays.

Statistical analysis. Data are represented as mean ± SD. To identify differences in tissue composition (DNA, sGAG, and collagen) between the control valve leaflets and the explanted leaflets at 16 and 24 weeks and that of native ovine valve leaflets, a 1-way analysis of variance was performed with Tukey's post-hoc testing. The number of values for the explanted valves after 8 weeks was too low (n = 2) to include in the statistical analyses. Differences were considered significant when $p < 0.05$. Statistics were performed using GraphPad Prism software (version 5.0d, San Diego, California).

Results

Implantation and in vivo performance of TEHVs. The transapical implantation procedures (n = 12) were successful. No perioperative morbidity or mortality occurred and all valves could be deployed successfully at the target site (Fig. 1, Online Video 1). In the early post-operative phase, 2 animals presented with valve migration into the right ventricular outflow tract and died within 24 h post-operatively. The



Figure 2 Echocardiography of TEHV

Representative examples of valve behavior directly after implantation **(A to C)**, after 4 **(D to F)**, 8 **(G to I)**, 16 **(J to L)**, and 24 weeks **(M to O)**. Valve performance was excellent with mobile and coapting leaflets at early follow-up time points **(A,B,D,E)**. Mobility of the leaflets was maintained, but coaptation decreased over time **(G,H,J,K,M,N)**, leading to central regurgitation after 16 **(L)** and 24 weeks follow-up **(O)**. TEHV = tissue-engineered heart valve. See accompanying Online Videos 2, 3, and 4.

remaining animals (n = 10) made a swift recovery and completed their respective follow-up without any complications. Serial echocardiography confirmed sufficient valve function with mobile leaflets and excellent coaptation at the early follow-up time points (Fig. 2, Online Videos 2 and 3). No central regurgitation was observed at 4 weeks (n = 10) and mild central regurgitation at 8 weeks (n = 10) (Table 1). Only minor paravalvular leakage was initially observed in some animals up to 1 week after implantation.

Long-term follow-up. While leaflet mobility was maintained on long-term follow-up, the coaptation slowly decreased over time (Fig. 2, Online Video 4), which was most likely due to merging of the leaflets with the valvular wall at the level of the hinge area as well as the occurrence of a single leaflet prolapse in some animals. Consequently, mild to moderate central regurgitation could be observed at 16 weeks (n = 8), that further increased to moderate central regurgitation at 24 weeks (n = 4), with 1 animal presenting with severe insufficiency. Functional measurements (Table 1) demonstrated stable mean and peak transvalvular pressure gradients over time (4.4 ± 1.6 mm Hg and 9.7 ± 3.0 mm Hg, respectively).

Macroscopic TEHV appearance. The implanted in vitro grown homologous TEHV revealed thin and shiny tissue formation in both valvular wall and leaflets (Figs. 3A to 3C). All explanted TEHVs demonstrated shiny and pliable leaflets and dense whitish valvular wall tissue, irrespective of the implantation period (Figs. 3D to 3L). In all explants, the valvular wall tissue was integrated into the surrounding native valvular wall. Excellent coaptation of the explanted valves was evident in the implant (Fig. 3A) and was maintained up to 8 weeks of implantation (Fig. 3D). Thereafter, valve closure was incomplete in line with the observed central regurgitation (Figs. 3G and 3J). Apparently, the line of attachment of the leaflets to the valvular wall shifted upward in time, indicating tissue merging process at the level of the hinge area (Figs. 3E, 3F, 3H, 3I, 3K, and 3L), associated with a reduction in leaflet size with time.

TEHV repopulation and remodeling. Prior to implantation the TEHVs revealed no cellular remnants (Figs. 4A, 4F, and 4K) and a well-developed extracellular matrix, mainly consisting of collagen demonstrating an efficient decellularization procedure (Figs. 4P, 4U, and 4Z). After TEHV deployment in the pulmonary position endogenous cellular repopulation occurred rapidly with first signs of cell infiltration as early as 5 h after implantation (Figs. 4B, 4G, and 4L). Both leaflets and wall tissues were homogeneously repopulated over time (Figs. 4C, 4D, 4H, 4I, 4M, and 4N), with fastest repopulation at highest densities in the wall. After 24 weeks, cell repopulation density in the leaflets (Fig. 4E) and hinge area (Fig. 4J) approached that in the valvular wall (Fig. 4O). Scaffold remnants remained longest visible in the leaflets (Figs. 4B to 4E) with local increased cell densities. Minimal depositions, most likely blood platelets and fibrin, were present at the surface of the whole valve after 5 h (Figs. 4B, 4G, and 4L), but disappeared with time. The valvular tissues demonstrated abundant amounts of collagen that increased in density over time, in particular in the hinge area (Figs. 4V, 4W to 4Y) and wall (Figs. 4AA to 4DD), and to a lesser extent in the leaflets (Figs. 4Q,R,S,T). Elastic matrix formation was evident in the wall at 8 weeks and later time points (Figs. 4BB to 4DD). In the hinge area the formation of elastic fibers was visible after 16 weeks (Figs. 4X and 4Y) and in the leaflets at 24 weeks (Fig. 4T). Calcification was not detected in any of the valves (data not shown).

TEHV cell phenotypes and distributions. Cells infiltrating the valve within 5 h after implantation were all

Table 1 Echocardiographic Assessment of TEHV Directly After Implantation, at 1, 4, 8, 16, and 24 Weeks Follow-Up

Follow-Up (Weeks)	N	Heart Rate (beats/min)	Mean dP (mm Hg)	Insufficiency Grade	Insufficiency Grade (per animal)
0	11	85 ± 18	3.5 ± 0.7	1.2 ± 0.4	1 (10/11) 2 (1/11)
1	10	111 ± 17	4.5 ± 1.0	1.2 ± 0.4	1 (8/10) 2 (2/10)
4	10	96 ± 18	4.3 ± 1.1	1.1 ± 0.3	1 (9/10) 2 (1/10)
8	10	103 ± 19	5.1 ± 1.3	2.0 ± 0.9	1 (3/10) 2 (5/10) 3 (1/10) 4 (1/10)
16	8	87 ± 21	5.0 ± 2.8	2.6 ± 0.9	1 (1/8) 2 (2/8) 3 (4/8) 4 (1/8)
24	4	101 ± 4	4.2 ± 2.0	3.2 ± 0.5	3 (3/4) 4 (1/4)
Overall mean	—	97 ± 20	4.4 ± 1.6	—	—

Values are mean ± SD unless otherwise indicated. Insufficiency (central regurgitation) was graded as none to trivial (1), mild (2), moderate (3), and severe (4). The values in parentheses indicate the number of animals that represented with the given insufficiency grade out of the total number of animals. dP = transvalvular pressure gradient; TEHV = tissue-engineered heart valve.



Figure 3 **Macroscopic Appearance of Decellularized In-Vitro Grown TEHV**

Macroscopic appearance of the implanted **(A to C)** and explanted **(D to L)** decellularized in vitro grown TEHV in closed configuration **(A,D,G,J)**, opened configuration **(B,E,H,K)**, and as cross section **(C,F,I,L)**. The implants and explants all revealed shiny and pliable leaflets. Complete closure was evident in the implant **(A)** and was maintained up to 8 weeks **(D)**, while being incomplete thereafter **(G,J)**. The line of attachment of leaflets to the wall moved upward in time **(arrows)**, associated with a reduction in leaflet size **(E,F,H,I,K,L)**. TEHV = tissue-engineered heart valve.

vimentin positive (Figs. 5A, 5E, and 5I) and alpha-smooth muscle actin (α-SMA) negative (Figs. 5M, 5Q, and 5U). After 8 weeks, vimentin positive cells were identified mainly in close vicinity of the polymeric scaffold remnants in the leaflet (Fig. 5B) and hinge area (Fig. 5F), while more homogenously distributed and in higher amounts in the valvular wall (Fig. 5J). The cells in the leaflet and hinge area were all α-SMA negative (Figs. 5N and 5R) and α-SMA positive in the valvular wall (Fig. 5V). After 16 weeks, homogenously distributed vimentin positive cells were observed in all regions of the valve (Figs. 5C, 5G, and 5K). These cells were α-SMA positive in the hinge area (Fig. 5S) and wall (Fig. 5W) and sparsely α-SMA positive in the leaflet (Fig. 5Q). After 24 weeks, vimentin positive cells were homogenously distributed over the valve (Figs. 5D, 5H, and 5L). The level of α-SMA seemed lower in the hinge area (Fig. 5T) and wall (Fig. 5X) as compared with the 16 weeks explants. In the leaflets, more α-SMA positive cells were identified (Fig. 5P) as compared with earlier time points.

After 8 weeks TEHV demonstrated partly confluent endothelial lining as observed by CD31 staining (Figs. 6A, 6D, and 6G). Similar features were observed at the surface of the explants at 16 (Figs. 6B, 6E, and 6H) and 24 weeks (Figs. 6C, 6F, and 6I). The cell lining showed the typical cobblestone morphology at all time points, representative for endothelial cells as visualized by scanning electron microscopy (Figs. 6J to 6O). The degree of endothelialization varied between locations and explants with decreasing endothelialization at the hinge area with implantation time (Figs. 6D to 6F) and increasing endothelialization of the leaflet (Figs. 6A to 6C) and valvular wall surface with implantation time (Figs. 6G to 6I).



Figure 4 **Histology of the Implanted and Explanted TEHV**

Hematoxylin and Eosin (H&E) (**A to O**) and Elastic von Gieson (EvG) (**P to DD**) staining of the implanted and explanted TEHV. The implants revealed no cellular remnants **(A,F,K)** and a well-developed extracellular matrix **(P,U,Z)**. The valvular tissues were homogeneously repopulated over time **(B to E,G to J,L to O)** with fastest repopulation at highest densities in the wall. Scaffold remnants **(closed arrows)** remained longest visible in the leaflets **(A to E)**. Minimal depositions **(asterisks)** were present at the surface after 5 h **(B,G,L)**, but disappeared with time. The valvular tissues demonstrated abundant amounts of collagen that increased in density over time **(Q,R,S,T,V,W,X,Y,AA,BB,CC,DD)**, mostly in the hinge area and wall. Elastic matrix formation **(dashed arrows)** was evident in all parts of the valve, appearing fastest in the wall **(BB to DD)**, followed by the hinge area **(X,Y)** and the leaflets **(T)**. Scale bars represent 200 μm. TEHV = tissue-engineered heart valve.

Quantitative TEHV tissue analyses. DNA content (Fig. 7A) of the leaflets increased with implantation time as compared with the values before implantation ($p < 0.01$ at 16 weeks and $p < 0.001$ after 24 weeks). After 16 weeks, DNA content was still lower than that in native leaflets ($p < 0.05$), but after 24 weeks the DNA content in the explanted TEHVs was similar to that in native ovine valve leaflets. The amount of sGAGs (Fig. 7B) was lower in TEHVs before implantation as compared with that in native leaflets ($p < 0.01$) and was still lower in the 16-week explants ($p < 0.05$). After 24 weeks sGAG content approached native values. Collagen content (Fig. 7C) was higher after 16 and 24 weeks in vivo as compared with the values of the TEHVs before implantation ($p < 0.05$). Collagen content was equal to that in native ovine leaflets at all time points.

Discussion

Since the emergence of transcatheter heart valve implantations, which today are mostly used in elderly inoperable patients, an expansion to younger patient populations is anticipated in the near future. A major limitation however—as in classical surgical bioprostheses—is the progressive dysfunctional deterioration inherent to the nonliving animal-derived tissue used in today's bioprostheses. Furthermore, accumulating clinical findings suggest that such degenerative



Figure 5 **Cellular Phenotypes in Explanted TEHV**

Vimentin **(A to L)** and alpha smooth muscle actin (α-SMA) (**M to X**) staining of TEHV. Vimentin positive cells were observed in all explants at all time points **(A to L)**, with high cell densities near the scaffold remnants. In the leaflets, no α-SMA expression was observed after 5 h **(M)** and 8 weeks **(N)**. First signs of α-SMA positive cells appeared at 16 weeks **(O)** and its level increased after 24 weeks **(P)**. The hinge area demonstrated similar features **(Q to T)**, though the level of expression seemed to decrease after 24 weeks **(T)** as compared with 16 weeks **(S)**. The cells in the valvular wall showed no α-SMA after 5 h **(U)**, but abundant expression of α-SMA at 8 weeks **(V)** that seemed to decrease at 16 weeks **(W)** and further at 24 weeks **(X)**. Scale bars represent 200 μm. TEHV = tissue-engineered heart valve.

processes may be even aggravated in transcatheter valves due to the substantial mechanical stresses during the crimping and deployment procedure. In the search for a next-generation technology platform to overcome the limitations of today's bioprosthetic transcatheter heart valve prostheses, the concept of HVTE using living autologous tissues with self-repair capacity has created substantial hope for future heart valve therapy concepts. In 2010, we have demonstrated the principal feasibility to merge transcatheter-based technologies and HVTE demonstrating transcatheter implantation of stent-based TEHVs as pulmonary valve replacements in a pre-clinical animal model (12). However, in this proof-of-concept study, the generation of the used TEHV followed the algorithm of the classical HVTE approach comprising complex logistical and financial efforts including cell and expansion, scaffold seeding, bioreactor in vitro pre-conditioning, and time-critical implantation coordination of the delicate, living, autologous tissue-engineered heart valves.

In this study, we simplified the previously used HVTE concept toward a substantially more translational and clinically relevant methodology demonstrating long-term in vivo functionality, host repopulation capacity, and matrix



Figure 6 **Endothelialization of Explanted TEHV**

CD31 staining **(A to I)** and scanning electron microscopy (SEM) (**J to O**) of explanted TEHV. Endothelialization was observed as a monolayer of CD31 positive cells lining the valve explant and was confirmed by its cobblestone morphology as observed by scanning electron microscopy (SEM). The degree of endothelialization varied between locations and explants, but was observed at all time points. Scale bars represent 200 μm **(A to I)** and 50 μm **(J to O)**. TEHV = tissue-engineered heart valve.

remodeling of off-the-shelf, tissue engineered decellularized homologous transcatheter TEHVs in sheep. Conceptually, off-the-shelf, homologous TEHVs carry significant advantages either when compared with decellularized xenogeneic/allogeneic natural heart valves (16,18) or to the technologically and logistically demanding "classical" HVTE approaches. By decellularization of homologous TEHV on the basis of biodegradable PGA/P4HB scaffolds, we are able to produce largely available off-the-shelf homologous starter matrices at any clinically relevant size without the risk for xenogeneic disease transmission (16). Importantly, this off-the-shelf concept greatly simplifies previous HVTE concepts with regard to financial and logistical efforts (16). Last but not least, these decellularized matrices are designed and adapted for transcatheter implantation, therewith further enhancing their clinical relevance.

Overall, the TEHV function was sufficient with mobile leaflets and excellent coaptation at the early follow-up time points. No central regurgitation was observed at 4 weeks and mainly mild central regurgitation at 8 weeks. While leaflet mobility as well as a low transvalvular mean gradient was maintained on all follow-up time points, valvular coaptation slowly decreased over time, which was most likely due to a principal design flaw of these prototype TEHVs resulting in merging of the leaflet base with the respective hinge areas. This may be primarily related to the prototype stent and valve design lacking important anatomical features such as sinuses and thus leading to nonphysiological loading and insufficient washout in the hinge area, in particular during diastole.

To ensure viability, prevent deterioration, and allow for growth and remodeling it is crucial that the host rapidly repopulates these matrices after implantation. In our study, the TEHVs demonstrated a remarkable repopulation and remodeling capacity, pointing to the high potential of this approach with regard to self-repair capacity.

Repopulation occurred rapidly already after a few hours. It was fastest in the valvular wall, followed by the hinge area and the leaflets, reaching similar DNA content to that of native valves. In line with that, the collagen amount reached native levels with increasing density over time and the

JACC Vol. 63, No. 13, 2014
April 8, 2014:1320–9



Figure 7 **Composition of TEHV Leaflets Before Implantation and After 8, 16, and 24 Weeks In Vivo**

The amount of DNA **(A),** sGAGs **(B),** and hydroxyproline **(C)** as a measure for collagen in TEHV leaflets before implantation **(white bars),** after 8 **(light grey bars)**, 16, and 24 weeks in vivo **(medium grey bars)**, and of native ovine pulmonary valve leaflets **(dark grey bars)**. The data for the 8-week explants was not taken into account in the statistical analyses, as the number of data points was too low (n = 2). DNA content increased in time, with values comparable to that in native leaflets after 24 weeks. Sulfated glycosaminoglycan (sGAG) values are still lower than that in native leaflets after 16 weeks, but approached native values after 24 weeks. Collagen content was higher after 16 and 24 weeks as compared with the values before implantation and was similar to those in native ovine leaflets. HYP = hydroxyproline; TEHV = tissue-engineered heart valve.

formation of elastic fibers was visible. Remodeling of the matrix occurred throughout the whole valve, but fastest in the wall, followed by the hinge area and the leaflets, and as such correlates with the observed rates of repopulation. Furthermore, endothelialization of the surfaces occurred at the valvular wall and the leaflets.

In comparison with native decellularized allogeneic or xenogeneic valve prostheses that have been repeatedly reported to show if at all only limited cell repopulation (4–8), repopulation of our TEHVs appears to be substantially more efficient. Importantly, thus far, repopulation of valve starter matrices was assumed to occur from the valve basis upward associated with remodeling of the valve matrix. This study suggests a potentially faster and more important route of repopulation, which is by blood-borne cells. The efficacy of repopulation and subsequent production and remodeling of extracellular matrix via this route may be very potent and its mechanisms are subject to subsequent studies.

Translation of this homologous off-the-shelf heart valve tissue engineering from the low-pressure pulmonary circulation to the systemic circulation appears feasible. Recent pilot experiments by our group have demonstrated structural integrity at systemic pressures of comparable valves (21–23). As soon as the stent and valve delivery system have been adapted to the aortic root, future studies will focus on long-term systemic valve replacements.

Conclusions

We demonstrate for the first time feasibility and long-term functionality of transcatheter delivered homologous off-the-shelf tissue-engineered heart valves with the potential for self-repair. The concept of off-the-shelf TEHV may represent a promising alternative to currently used valve prostheses as of their rapid host cell repopulation and remodeling capabilities toward native valve features within a short time-span. Moreover, the off-the-shelf TEHV concept may significantly simplify previous, classical HVTE concepts toward clinical translation.

Study limitations. Valvular coaptation decreased over time by merging of the leaflet base with the respective hinge areas. This shortcoming of the prototype TEHV requires stent and scaffold design modifications and optimizations (i.e., the implementation of anatomical sinuses [24]) to ensure and further improve long-term functionality of these next generation valves.

Acknowledgments

The authors thank Marina van Doeselaar (Department of Biomedical Engineering, TU/e) for help with TEHV culture, Pia Fuchs (Department of Surgical Research, USZ) for her support as to the histological examination, the Laboratory for Special Techniques (Institute for Clinical Pathology, USZ) as to the (immuno-) histochemical examination, and Mr. Klaus Marquardt (EMZ, University

of Zürich) as to the scanning electron microscopy investigations.

Reprint requests and correspondence: Dr. Simon P. Hoerstrup, Heart Center Zürich, University and University Hospital Zürich, Raemistrasse 100, 8091 CH-Zürich, Switzerland. E-mail: simon_philipp.hoerstrup@usz.ch.

REFERENCES

1. Rosengart TK, Feldman T, Borger MA, et al. Percutaneous and minimally invasive valve procedures: a scientific statement from the American Heart Association Council on Cardiovascular Surgery and Anesthesia, Council on Clinical Cardiology, Functional Genomics and Translational Biology Interdisciplinary Working Group, and Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2008;117:1750–67.
2. Pibarot P, Dumesnil JG. Prosthetic heart valves: selection of the optimal prosthesis and long-term management. Circulation 2009;119:1034–48.
3. Yacoub MH, Takkenberg JJM. Will heart valve tissue engineering change the world? Nat Clin Pract Cardiovasc Med 2005;2:60–1.
4. Erdbrugger W, Konertz W, Dohmen PM, Posner S, Ellerbrok H, Brodde OE. Decellularized xenogenic heart valves reveal remodeling and growth potential in vivo. Tissue Eng 2006;12:2059–68.
5. Hopkins RA, Jones AL, Wolfinbarger L, Moore MA, Bert AA, Lofland GK. Decellularization reduces calcification while improving both durability and 1-year functional results of pulmonary homograft valves in juvenile sheep. J Thorac Cardiovasc Surg 2009;137:907–13.
6. Baraki H, Tudorache I, Braun M, et al. Orthotopic replacement of the aortic valve with decellularized allograft in a sheep model. Biomaterials 2009;30:6240–6.
7. Quinn RW, Hilbert SL, Bert AA, et al. Performance and morphology of decellularized pulmonary valves implanted in juvenile sheep. Ann Thorac Surg 2011;92:131–7.
8. Honge JL, Funder J, Hansen E, Dohmen PM, Konertz W, Hasenkam JM. Recellularization of aortic valves in pigs. Eur J Cardiothorac Surg 2011;39:829–34.
9. Shinoka T, Breuer CK, Tanel RE, et al. Tissue engineering heart valves: valve leaflet replacement study in a lamb model. Ann Thorac Surg 1995;60:S513–6.
10. Shinoka T, Ma PX, Shum-Tim D, et al. Tissue engineered heart valves. Autologous valve leaflet replacement study in a lamb model. Circulation 1996;94:II164–8.
11. Flanagan TC, Sachweh JS, Frese J. In vivo remodeling and structural characterization of fibrin-based tissue-engineered heart valves in the adult sheep model. Tissue Eng Part A 2009;15:2965–76.
12. Schmidt D, Dijkman PE, Driessen-Mol A, et al. Minimally-invasive implantation of living tissue engineered heart valves: a comprehensive approach from autologous vascular cells to stem cells. J Am Coll Cardiol 2010;56:510–20.
13. Vlimmeren van MA, Driessen-Mol A, Oomens CWJ, Baaijens FPT. An in vitro model system to quantify stress generation, compaction, and retraction in engineered heart valve tissue. Tissue Eng Part C Methods 2011;17:983–91.
14. Syedain ZH, Lahti MT, Johnson SL, et al. Implantation of a tissue-engineered heart valve from human fibroblasts exhibiting short term function in the sheep pulmonary artery. Cardiovasc Eng Tech 2011;2:101–12.
15. Dijkman PE, Driessen-Mol A, Heer de LM, et al. Trans-apical versus surgical implantation of autologous ovine tissue-engineered heart valves. J Heart Valve Dis 2012;21:670–8.
16. Dijkman PE, Driessen-Mol A, Frese L, Hoerstrup SP, Baaijens FP. Decellularized homologous tissue-engineered heart valves as off-the-shelf alternatives to xeno- and homografts. Biomaterials 2012;33:4545–54.
17. Syedain ZH, Bradee AR, Kren S, Taylor DA, Tranquillo RT. Decellularized tissue-engineered heart valve leaflets with recellularization potential. Tissue Eng Part A 2013;19:1–11.
18. Weber B, Dijkman PE, Sherman J, et al. Off-the-shelf human decellularized tissue-engineered heart valves in a non-human primate model. Biomaterials 2013;34:7269–80.
19. Mol A, Driessen NJB, Rutten MCM, Hoerstrup SP, Bouten CVC, Baaijens FPT. Tissue engineering of human heart valve leaflets: a novel bioreactor for a strain-based conditioning approach. Ann Biomed Eng 2005;33:1778–88.
20. Guide for the Care and Use of Laboratory Animals 8th edition. Washington, DC: National Academies Press (US), 2011.
21. Emmert MY, Weber B, Behr L, et al. Transapical aortic implantation of autologous marrow stromal cell-based tissue-engineered heart valves: First experiences in the systemic circulation. J Am Coll Cardiol Intv 2011;4:822–3.
22. Emmert MY, Weber B, Wolint P, et al. Stem cell-based transcatheter aortic valve implantation: First experiences in a pre-clinical model. J Am Coll Cardiol Intv 2012;5:874–83.
23. Emmert MY, Weber B, Behr L, et al. Transcatheter aortic valve implantation using anatomically oriented, marrow stromal cell-based, stented, tissue-engineered heart valves: Technical considerations and implications for translational cell-based heart valve concepts. Eur J Cardiothorac Surg 2013;45:61–8.
24. Dodge-Khatami A, Hallhagen S, Limacher K, Soderberg B, Jenni R. Minimally invasive insertion of an equine stented pulmonary valve with a built-in sinus portion in a sheep model. Catheter Cardiovasc Interv 2012;79:654–8.

Key Words: off-the-shelf tissue engineering ■ self-repair ■ tissue-engineered heart valves ■ transcatheter valve implantation.

APPENDIX

For an expanded Methods section and supplemental videos, please see the online version of this article.